Although ibrutinib is an irreversible covalent inhibition of BTK, it showed good therapeutic effect and safety in the treatment of the first-line and relapsed/refractory CLL/SLL. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.